Live Breaking News & Updates on குழந்தை பாக்டீரியா சிகிச்சை

Stay updated with breaking news from குழந்தை பாக்டீரியா சிகிச்சை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Infant Bacterial Therapeutics AB: Infant Bacterial Therapeutics CFO leaves the company


Infant Bacterial Therapeutics AB: Infant Bacterial Therapeutics CFO leaves the company
Infant Bacterial Therapeutics ABs CFO Daniel Mackey has decided to leave the company to pursue new challenges. He will remain in his current role during his notice period. Michael Owens will be acting CFO when Daniel leaves the company and until his replacement is in place. The recruitment process has already been initiated.
I would like to take this opportunity to thank Daniel and wish him every success in the future , says Staffan Strömberg, Chief Executive Officer of IBT.
About Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) is a pharmaceutical company with a product in Phase III with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants. ....

Michael Owens , Daniel Mackey , Infant Bacterial Therapeutics , Staffan Str , Chief Executive Officer , Nasdaq Stockholm , மைக்கேல் ஓவந்ஸ் , டேனியல் மேக்கி , குழந்தை பாக்டீரியா சிகிச்சை , பணியாளர் ஸ்ட்ர் , தலைமை நிர்வாகி அதிகாரி , நாஸ்டாக் ஸ்டாக்‌ஹோல்ம் ,

Investegate |Infant Bacterial Therapeutics Announcements | Infant Bacterial Therapeutics: Infant Bacterial Therapeutics CFO leaves the company


A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
1. Obtains access to the information in a personal capacity;
2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so; ....

Michael Owens , Daniel Mackey , Infant Bacterial Therapeutics , Staffan Str , Chief Executive Officer , Nasdaq Stockholm , Investegate Announcements , Investegate Company Announcements , Infant Bacterial Therapeutics , Lobenewswire And Globenewswire , மைக்கேல் ஓவந்ஸ் , டேனியல் மேக்கி , குழந்தை பாக்டீரியா சிகிச்சை , பணியாளர் ஸ்ட்ர் , தலைமை நிர்வாகி அதிகாரி , நாஸ்டாக் ஸ்டாக்‌ஹோல்ம் ,

Investegate |Infant Bacterial Therapeutics Announcements | Infant Bacterial Therapeutics: Annual General Meeting of Infant Bacterial Therapeutics CEO speech


A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
1. Obtains access to the information in a personal capacity;
2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so; ....

Daniel Mackey , Annual General Meeting , Infant Bacterial Therapeutics , Nasdaq Stockholm , டேனியல் மேக்கி , ஆண்டு ஜநரல் சந்தித்தல் , குழந்தை பாக்டீரியா சிகிச்சை , நாஸ்டாக் ஸ்டாக்‌ஹோல்ம் ,